EULAR 2011 - Vidofludimus Superior to Cyclophosphamide (CYC) and MMF (cellcept) in an Experimental Systemic Lupus Erythematosus (SLE) Model.
Vidofludimus was as effective as CYC and MMF in inhibiting progression parameters of renal disease. Furthermore, vidofludimus improved activity and chronicity indices, markers of renal inflammation. Business Wire. 05/27/11. (Also see: Lupus)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.
EULAR 2011 - Vidofludimus Superior to Cyclophosphamide and MMF (cellcept) in an Experimental Systemic Lupus Erythematosus Model
No replies to this topic